Compare Novavax Inc (NVAX) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Banco Santander SA — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while Banco Santander SA trades at $13.74 (market cap $191.46B). The key difference: Banco Santander SA is far larger — about 147.3× Novavax Inc's market cap, and Banco Santander SA pays a 2.09% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SAN | |
|---|---|---|
Market Cap | $1.30B | $191.46B |
Sector | Health | Financials |
52-Week High | $11.19 | $14.37 |
52-Week Low | $6.22 | $8.40 |
Enterprise Value | $800.50M | — |
Dividend Yield | — | 2.09% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
